An interventional study of personal narrative book in Hysterectomy, Anxiety and Depression, sponsored by Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI). Recruiting at 4 sites in France. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI) · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in Depression with a site in France — 63 open to participants now, 67 under way, 2 of them phase 3. Depression · France.
Among the 266 studies in Depression with a site in France, this one is the 74th largest by planned enrollment of the 185 interventional ones that give a count, is one of 17 that started in 2026, is one of 133 with no phase, reaches primary completion later than 46 of the 66 other live ones, and was the 254th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →63 of the 266 studies in Depression with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Healthy volunteers
Hospital Ambroise Paré Paris · Sites in France
Ages 18–80
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 7–25
Nantes University Hospital · Sites in France
Ages 18+
ThIA Santé Mentale · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 42 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 30 · Phase 4 9
First in 1990; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 156 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 120 across the 185 interventional studies, 158 across the 81 observational. Of the 157 that completed or were terminated, 18 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 266 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI) as lead sponsor.
Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI) has 1 study filed under Depression — fewer than ten, so there is no comparison to draw.
18 of the studies in Depression with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05632757Assistance Publique Hopitaux De MarseilleAnticipated Patient and Caregiver Burden | 2026-12-22 |
| NCT05074901University of BordeauxVirtual Agents-based Digital Interventions to Improve Health | 2026-12-31 |
| NCT06747793University Hospital, ToulouseVirtual Reality to Reduce the Anxiety in Critically Ill Patient | 2027-01 |
| NCT05661383Hôpital le VinatierOlfactory and Brain Stimulations in Treatment-resistant Depression | 2027-01-27 |
| NCT05149742Assistance Publique - Hôpitaux de ParisDeafness and Cognition in Middle-aged Adults | 2027-05-24 |
Add all 18 to your calendar (.ics) → With an account.
Among the 266 studies in Depression with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this interventional clinical trial involving minimal risks and constraints is to evaluate whether an innovative approach to managing catastrophizing in the preoperative context of hysterectomy improves psychological outcomes compared to usual care in women of childbearing age who have been informed of an indication for hysterectomy.
The main questions it aims to answer are:
Researchers will compare standard care (CNGOF information leaflet with psychological consultation if needed) with an intervention including a personal narrative book in addition to standard care, to see if the intervention improves emotional regulation, psychological well-being, and satisfaction.
Participants will:
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
This study's planned enrollment of 156 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Browse Depression studies →This is the only study on the registry with Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI) as lead sponsor.
Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CNGOF information leaflet with a consultation with a psychologist or other additional supportive measures if needed.
CNGOF information leaflet, personal narrative book, and a consultation with a psychologist or other additional supportive measures if needed.
Other: personal narrative book
Reading a personal narrative book written by a patient who underwent a hysterectomy
Adaptive regulation
The adaptative regulation is measured using the Cognitive Emotion Regulation Questionnaire - Adaptive (CERQ-A) wich include five adaptive subscales . Scores range from 20 to 100, with higher scores indicating better adaptive regulation.
Time frame: between inclusion (D0) and surgery (S0), occurring 1 to 3 months later.
Anxiety and depression
The outcome is measured using the Hospital Anxiety and Depression Scale (HADS). The scale includes two subscales: Anxiety (HADS-A) and Depression (HADS-D). Each subscale ranges from 0 to 21, with higher scores indicating more severe symptoms.
Time frame: between inclusion (D0) and surgery (S0), occurring 1 to 3 months later.
Adaptive and maladaptive regulation
This outcomes is measured using the Cognitive Emotion Regulation Questionnaire (CERQ). Two composite scores are derived: adaptive regulation and maladaptive regulation. The adaptative regulation is measured using the Cognitive Emotion Regulation Questionnaire - Adaptive (CERQ-A) wich include five adaptive subscales . Scores range from 20 to 100, with higher scores indicating better adaptive regulation. The maldaptative regulation is measured using the Cognitive Emotion Regulation Questionnaire - Non-Adaptive (CERQ-NA) wich include four maladaptive subscales. Scores range from 16 to 80, with higher scores indicating greater use of maladaptive regulation strategies.
Time frame: between inclusion (D0) and surgery (S0), occurring 1 to 3 months later.
Catastrophizing
The outcome is measured using the Symptom Catastrophizing Scale (SCS), a 7-item questionnaire assessing catastrophic thinking related to symptoms. Total scores range from 0 to 14.
Time frame: between inclusion (D0) and surgery (S0), occurring 1 to 3 months later.
Use of additional supportive measures
The questionnaire is completed by the physician based on the prescription made or recommended to the patient. The questions are independent and do not generate a score.
Time frame: at the inclusion (D0)
Use of additional supportive measures
The questionnaire is completed by the patient. The questions are independent and do not generate a score.
Time frame: Postoperative, occuring 1 to 3 months after inclusion.
Patient satisfaction
The outcome is measured using the Likert-type satisfaction scale to determine satisfaction with their care. Responses range from "extremely satisfied" to "extremely dissatisfied."
Time frame: Postoperative, occuring 1 to 3 months after inclusion.
Started May 2026 (actual). Primary completion is estimated for Jan 2028, 20 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 20 months is close to that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.